To access the full text documents, please follow this link: http://hdl.handle.net/2445/130889
dc.contributor.author | Montalbo Calafell, Ruth |
---|---|
dc.contributor.author | Lozano Salvatella, Juan José |
dc.contributor.author | Izquierdo Reyes, Laura |
dc.contributor.author | Ingelmo-Torres, Mercedes |
dc.contributor.author | Baños, Carmen |
dc.contributor.author | Palou, Joan |
dc.contributor.author | Heijden, Antoine G. van der |
dc.contributor.author | Medina, Rafael |
dc.contributor.author | Schmidbauer, Joerg |
dc.contributor.author | Prat Aparicio, Aleix |
dc.contributor.author | Ribal, María José |
dc.contributor.author | Alcaraz Asensio, Antonio |
dc.contributor.author | Mengual Brichs, Lourdes |
dc.date | 2019-03-26T16:37:49Z |
dc.date | 2020-12-31T06:10:16Z |
dc.date | 2019-02-07 |
dc.date | 2019-03-26T16:37:49Z |
dc.identifier | 1931-5244 |
dc.identifier | 686534 |
dc.identifier | 30771285 |
dc.identifier.uri | http://hdl.handle.net/2445/130889 |
dc.description | This study aimed to improve our previous urine gene expression classifiers focusing on the detection of non-high-risk non-muscle-invasive bladder cancer (NMIBC), and develop a new classifier able to decrease the frequency of cystoscopies during bladder cancer (BC) patients' surveillance. A total of 597 urines from BC patients, controls and patients in follow-up for BC (PFBC) were included. The study has 3 phases. In the urinary biomarker discovery phase, 84 urines from BC and control patients were retrospectively included and analyzed by Ribonucleic Acid (RNA) sequencing. In the classifier development phase, a total of 132 selected genes from previous phase were evaluated by nCounter in 214 prospectively collected urines from PFBC (98 with tumor). A diagnostic classifier was generated by logistic regression. Finally, in the classifier validation phase, a multicentric and international cohort of 248 urines (134 BC and 114 nonrecurrent PFBC) was used to validate classifier performance. A total of 521 genes were found differentially expressed between non-high-risk NMIBC samples and all other groups (P < 0.05). An 8-gene diagnostic classifier with an area under curve (AUC) of 0.893 was developed. Validation of this classifier in a cohort of PFBC achieved an overall sensitivity (SN) and a negative predictive value (NPV) of 96% and 97%, respectively (AUC = 0.823). Notably, this accuracy was maintained in non-high-risk NMIBC group (SN = 94%; NPV = 98%). In conclusion, this 8-gene expression classifier has high SN and NPV in a real clinical scenario. The use of this classifier can reduce the number of follow-up cystoscopies in PFBC, although assessing its final place in clinical setting is necessary. |
dc.format | 12 p. |
dc.format | application/pdf |
dc.language | eng |
dc.publisher | Elsevier |
dc.relation | Versió postprint del document publicat a: https://doi.org/10.1016/j.trsl.2019.02.003 |
dc.relation | Translational Research, The Journal of Laboratory and Clinical Medicine, 2019, vol. S1931-5244, num. 19, p. 30025-30028 |
dc.relation | https://doi.org/10.1016/j.trsl.2019.02.003 |
dc.rights | cc-by-nc-nd (c) Central Society for Clinical Research , 2019 |
dc.rights | http://creativecommons.org/licenses/by-nc-nd/3.0/es |
dc.rights | info:eu-repo/semantics/openAccess |
dc.subject | Diagnòstic per la imatge |
dc.subject | Càncer de bufeta |
dc.subject | Expressió gènica |
dc.subject | Diagnostic imaging |
dc.subject | Bladder cancer |
dc.subject | Gene expression |
dc.title | Ability of a urine gene expression classifier to reduce the number of follow up cystoscopies in bladder cancer patients |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/acceptedVersion |